Dev Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 790.45%
- Profit Growth 193.33%
- Ebitda 185.18%
- Net Worth 97.09%
- Total Assets 252.63%
About Dev Lifesciences
Dev Lifesciences Private Limited (DLPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 August 2014 and has a history of Ten years and five months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Tapasya Rane and Devdatta Rane serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74900MH2014PTC256843
- Company No.
256843
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Dev Lifesciences Private Limited offer?
Dev Lifesciences Private Limited offers a wide range of products and services, including Marketing Services & Consultants, Marketing Services.
Who are the key members and board of directors at Dev Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tapasya Rane  | Director | 04-Aug-2014 | Current |
| Devdatta Rane | Director | 04-Aug-2014 | Current |
Financial Performance of Dev Lifesciences.
Dev Lifesciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 790.45% increase. The company also saw a substantial improvement in profitability, with a 193.33% increase in profit. The company's net worth Soared by an impressive increase of 97.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dev Lifesciences?
In 2017, Dev Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Devz Media & Advertising Private LimitedTapasya Rane and Devdatta Rane are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dev Lifesciences?
Unlock and access historical data on people associated with Dev Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dev Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dev Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.